Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 85

1.

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant.

von Tresckow B, Müller H, Eichenauer DA, Glossmann JP, Josting A, Böll B, Klimm B, Sasse S, Fuchs M, Borchmann P, Engert A.

Leuk Lymphoma. 2014 Aug;55(8):1922-4. doi: 10.3109/10428194.2013.854888. Epub 2014 Jan 28. No abstract available.

PMID:
24138304
2.

Improvement in the outcome of invasive fusariosis in the last decade.

Nucci M, Marr KA, Vehreschild MJ, de Souza CA, Velasco E, Cappellano P, Carlesse F, Queiroz-Telles F, Sheppard DC, Kindo A, Cesaro S, Hamerschlak N, Solza C, Heinz WJ, Schaller M, Atalla A, Arikan-Akdagli S, Bertz H, Galvão Castro C Jr, Herbrecht R, Hoenigl M, Härter G, Hermansen NE, Josting A, Pagano L, Salles MJ, Mossad SB, Ogunc D, Pasqualotto AC, Araujo V, Troke PF, Lortholary O, Cornely OA, Anaissie E.

Clin Microbiol Infect. 2014 Jun;20(6):580-5. doi: 10.1111/1469-0691.12409. Epub 2013 Nov 18.

3.

Prognostic factors in Hodgkin lymphoma.

Josting A.

Expert Rev Hematol. 2010 Oct;3(5):583-92. doi: 10.1586/ehm.10.50. Review.

PMID:
21083475
4.

Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma.

Josting A, Müller H, Borchmann P, Baars JW, Metzner B, Döhner H, Aurer I, Smardova L, Fischer T, Niederwieser D, Schäfer-Eckart K, Schmitz N, Sureda A, Glossmann J, Diehl V, DeJong D, Hansmann ML, Raemaekers J, Engert A.

J Clin Oncol. 2010 Dec 1;28(34):5074-80. doi: 10.1200/JCO.2010.30.5771. Epub 2010 Oct 25.

PMID:
20975066
5.

Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.

Scholz M, Engert A, Franklin J, Josting A, Diehl V, Hasenclever D, Loeffler M; German Hodgkin's Lymphoma Study Group.

Ann Oncol. 2011 Mar;22(3):681-8. doi: 10.1093/annonc/mdq408. Epub 2010 Aug 18.

PMID:
20720088
6.

Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG).

Halbsguth TV, Nogová L, Mueller H, Sieniawski M, Eichenauer DA, Schober T, Nisters-Backes H, Borchmann P, Diehl V, Engert A, Josting A.

Blood. 2010 Sep 23;116(12):2026-32. doi: 10.1182/blood-2009-11-253211. Epub 2010 Jun 15.

7.

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

J Clin Oncol. 2010 May 1;28(13):2239-45. doi: 10.1200/JCO.2009.25.1835. Epub 2010 Apr 5.

PMID:
20368566
8.

Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.

Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, Halbsguth T, Fuchs M, Diehl V, Engert A.

Ann Oncol. 2008 Oct;19(10):1795-801. doi: 10.1093/annonc/mdn376. Epub 2008 Jun 9.

PMID:
18544558
9.

Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.

Nogová L, Reineke T, Brillant C, Sieniawski M, Rüdiger T, Josting A, Bredenfeld H, Skripnitchenko R, Müller RP, Müller-Hermelink HK, Diehl V, Engert A; German Hodgkin Study Group.

J Clin Oncol. 2008 Jan 20;26(3):434-9. Epub 2007 Dec 17.

PMID:
18086799
10.

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).

Sieniawski M, Reineke T, Nogova L, Josting A, Pfistner B, Diehl V, Engert A.

Blood. 2008 Jan 1;111(1):71-6. Epub 2007 Sep 21.

11.

Successful carboxypeptidase G2 rescue of a high-risk elderly Hodgkin lymphoma patient with methotrexate intoxication and renal failure.

Sieniawski M, Rimpler M, Herrmann R, Josting A.

Leuk Lymphoma. 2007 Aug;48(8):1641-3. No abstract available.

PMID:
17701600
12.

Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.

Sieniawski M, Franklin J, Nogova L, Glossmann JP, Schober T, Nisters-Backes H, Diehl V, Josting A.

J Clin Oncol. 2007 May 20;25(15):2000-5. Epub 2007 Apr 9.

PMID:
17420510
13.

Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity.

Wilde S, Jetter A, Rietbrock S, Kasel D, Engert A, Josting A, Klimm B, Hempel G, Reif S, Jaehde U, Merkel U, Busse D, Schwab M, Diehl V, Fuhr U.

Clin Pharmacokinet. 2007;46(4):319-33.

PMID:
17375983
14.

Rituximab added to an intensified salvage chemotherapy program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma.

Sieniawski M, Staak O, Glossmann JP, Reineke T, Scheuss H, Diehl V, Engert A, Josting A.

Ann Hematol. 2007 Feb;86(2):107-15. Epub 2006 Nov 14.

PMID:
17103169
15.

Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease.

Seyfarth B, Josting A, Dreyling M, Schmitz N.

Br J Haematol. 2006 Apr;133(1):3-18. Review. Erratum in: Br J Haematol. 2006 Aug;134(4):449.

PMID:
16512824
16.

Advances in biology, diagnostics, and treatment of Hodgkin's disease.

Küppers R, Yahalom J, Josting A.

Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):66-76. Review.

17.

[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma].

Borchmann P, Behringer K, Josting A, Rueffer JU, Schnell R, Diehl V, Engert A, Kvasnicka HM, Thiele J.

Pathologe. 2006 Feb;27(1):47-52. German.

PMID:
16369761
18.

BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group.

Rüffer JU, Ballova V, Glossmann J, Sieber M, Franklin J, Nogova L, Diehl V, Josting A; German Hodgkin Study Group.

Leuk Lymphoma. 2005 Nov;46(11):1561-7.

PMID:
16236610
19.

Role of hematotoxicity and sex in patients with Hodgkin's lymphoma: an analysis from the German Hodgkin Study Group.

Klimm B, Reineke T, Haverkamp H, Behringer K, Eich HT, Josting A, Pfistner B, Diehl V, Engert A; German Hodgkin Study Group.

J Clin Oncol. 2005 Nov 1;23(31):8003-11. Epub 2005 Oct 3.

PMID:
16204002
20.

Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.

Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A.

J Clin Oncol. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6.

PMID:
16145065

Supplemental Content

Loading ...
Support Center